The future of PARP inhibitors in prostate cancer

Bookmark and Share
Published: 2 Jul 2020
Views: 172
Dr Elena Castro - Spanish National Cancer Research Center, Madrid, Spain

Dr Elena Castro speaks to ecancer about her thoughts on the future of PARP inhibitors in prostate cancer, including possible treatment combinations and the potential role of these agents as an adjuvant therapy.

She states that patients with a BRCA2 mutation experience a very poor prognosis, and PARP inhibitors could be considered as a treatment option for earlier stages of the disease in the future.

Dr Castro emphasises that trials are needed to further characterise the role of PARP inhibitors in prostate cancer, and notes that there are trials underway that are exploring the combination of PARP inhibitors with checkpoint inhibitors, or androgen-receptor signalling inhibitors.

This programme has been supported by an unrestricted educational grant from Pfizer.